MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573313 | Name: ent-Atorvastatin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ent-Atorvastatin is a selective and competitive HMGCR (HMG-CoA reductase) inhibitor

Chemical Structure

ent-Atorvastatin
ent-Atorvastatin
CAS#501121-34-2

Theoretical Analysis

MedKoo Cat#: 573313

Name: ent-Atorvastatin

CAS#: 501121-34-2

Chemical Formula: C33H35FN2O5

Exact Mass: 558.2530

Molecular Weight: 558.65

Elemental Analysis: C, 70.95; H, 6.32; F, 3.40; N, 5.01; O, 14.32

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
3S,5S-Atorvastatin, Atorvastatin calcium trihydrate impurity E, ent-Atorvastatin; (3S,5S)-Atorvastatin; S,S-Atorvastatin;
IUPAC/Chemical Name
(3S,5S)-7-(2-(4-Fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
InChi Key
XUKUURHRXDUEBC-SVBPBHIXSA-N
InChi Code
1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m0/s1
SMILES Code
CC(C)c1c(c(c(n1CC[C@@H](C[C@@H](CC(=O)O)O)O)c2ccc(cc2)F)c3ccccc3)C(=O)Nc4ccccc4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 558.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Qiu S, Zhuo W, Sun C, Su Z, Yan A, Shen L. Effects of atorvastatin on chronic subdural hematoma: A systematic review. Medicine (Baltimore). 2017 Jun;96(26):e7290. doi: 10.1097/MD.0000000000007290. Erratum in: Medicine (Baltimore). 2017 Jul 21;96(29):e7616. PMID: 28658127; PMCID: PMC5500049. 2: Kogawa AC, Pires AEDT, Salgado HRN. Atorvastatin: A Review of Analytical Methods for Pharmaceutical Quality Control and Monitoring. J AOAC Int. 2019 May 1;102(3):801-809. doi: 10.5740/jaoacint.18-0200. Epub 2018 Dec 18. PMID: 30563586. 3: Taniguti EH, Ferreira YS, Stupp IJV, Fraga-Junior EB, Doneda DL, Lopes L, Rios-Santos F, Lima E, Buss ZS, Viola GG, Vandresen-Filho S. Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. Brain Res Bull. 2019 Mar;146:279-286. doi: 10.1016/j.brainresbull.2019.01.018. Epub 2019 Jan 25. PMID: 30690060. 4: Su H, Lu Y, Ma C, Li H, Su X. Impact of atorvastatin on erectile dysfunction: A meta-analysis and systematic review. Andrologia. 2022 Jul;54(6):e14408. doi: 10.1111/and.14408. Epub 2022 Feb 27. PMID: 35224753. 5: Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, Mao Y, Yuan X, Fei Z, Zhao Y, Yu X, Poon WS, Zhu X, Liu N, Kang D, Sun T, Jiao B, Liu X, Yu R, Zhang J, Gao G, Hao J, Su N, Yin G, Zhu X, Lu Y, Wei J, Hu J, Hu R, Li J, Wang D, Wei H, Tian Y, Lei P, Dong JF, Zhang J. Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. JAMA Neurol. 2018 Nov 1;75(11):1338-1346. doi: 10.1001/jamaneurol.2018.2030. PMID: 30073290; PMCID: PMC6248109. 6: Yu L, Liu S, Zhou R, Sun H, Su X, Liu Q, Li S, Ying J, Zhao F, Mu D, Qu Y. Atorvastatin inhibits neuronal apoptosis via activating cAMP/PKA/p-CREB/BDNF pathway in hypoxic-ischemic neonatal rats. FASEB J. 2022 Apr;36(4):e22263. doi: 10.1096/fj.202101654RR. PMID: 35303316. 7: Abolghasemi R, Ebrahimi-Barough S, Bahrami N, Ai J. Atorvastatin Inhibits Viability and Migration of MCF7 Breast Cancer Cells. Asian Pac J Cancer Prev. 2022 Mar 1;23(3):867-875. doi: 10.31557/APJCP.2022.23.3.867. PMID: 35345358; PMCID: PMC9360942. 8: Hu N, Chen C, Wang J, Huang J, Yao D, Li C. Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-signaling Pathway and HMGCR Expression in the Liver. Int J Mol Sci. 2021 Oct 14;22(20):11107. doi: 10.3390/ijms222011107. PMID: 34681767; PMCID: PMC8538474. 9: Liping Z, Xiufang L, Tao Y, Baomin Z, Houshuai T. Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis. Pak J Pharm Sci. 2018 Sep;31(5(Special)):2203-2208. PMID: 30463813. 10: Famularo G, Sarrecchia C. Atorvastatin-Associated Gynecomastia. Ann Pharmacother. 2021 Oct;55(10):1300-1301. doi: 10.1177/1060028021988994. Epub 2021 Jan 20. PMID: 33472378. 11: Chen J, Yan J, Li S, Zhu J, Zhou J, Li J, Zhang Y, Huang Z, Yuan L, Xu K, Chen W, Ye W. Atorvastatin inhibited TNF-α induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-κB signaling. Cell Cycle. 2021 Oct;20(20):2160-2173. doi: 10.1080/15384101.2021.1973707. Epub 2021 Sep 8. PMID: 34494933; PMCID: PMC8565837. 12: Shaghaghi Z, Alvandi M, Farzipour S, Dehbanpour MR, Nosrati S. A review of effects of atorvastatin in cancer therapy. Med Oncol. 2022 Dec 2;40(1):27. doi: 10.1007/s12032-022-01892-9. PMID: 36459301. 13: Ning Y, Huang P, Chen G, Xiong Y, Gong Z, Wu C, Xu J, Jiang W, Li X, Tang R, Zhang L, Hu M, Xu J, Xu J, Qian H, Jin C, Yang Y. Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p/Stat1 pathway. BMC Med. 2023 Mar 16;21(1):96. doi: 10.1186/s12916-023-02778-x. PMID: 36927608; PMCID: PMC10022054. 14: Shah U, Shah A, Patel S, Patel A, Patel M, Solanki N, Patel S, Patel A, Patel V, Patel B. Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment. CNS Neurol Disord Drug Targets. 2023;22(10):1462-1471. doi: 10.2174/1871527322666221005124808. PMID: 36200162. 15: Oliveira-Junior SA, Carvalho MR, Mendonça MLM, Martinez PF. Anti- Inflammatory Effects of Atorvastatin Therapy in Metabolic Syndrome. Arq Bras Cardiol. 2021 Oct;117(4):748-749. English, Portuguese. doi: 10.36660/abc.20210720. PMID: 34709301; PMCID: PMC8528359. 16: Sun J, Xu W, Wu Z, Cao C, Tan Y, Zhu M, Wu H, Yu J. Immunomodulatory effects of atorvastatin on MRL/lpr mice. Adv Rheumatol. 2022 Dec 5;62(1):47. doi: 10.1186/s42358-022-00282-z. PMID: 36471414; PMCID: PMC9735199. 17: Elsayed MM, Ayman EM. Atorvastatin can delay arterial stiffness progression in hemodialysis patients. Int Urol Nephrol. 2022 Nov;54(11):2969-2976. doi: 10.1007/s11255-022-03231-3. Epub 2022 May 18. PMID: 35585282; PMCID: PMC9534972. 18: Stein B, Ward T, Hale G, Lyver E. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg. Ann Pharmacother. 2020 May;54(5):405-413. doi: 10.1177/1060028019888487. Epub 2019 Nov 12. PMID: 31718234. 19: Sánchez-López E, Gómara MJ, Haro I. Atorvastatin-loaded peptide amphiphiles against corneal neovascularization. Nanomedicine (Lond). 2023 Jul;18(17):1095-1108. doi: 10.2217/nnm-2023-0133. Epub 2023 Aug 23. PMID: 37610088. 20: Gatto M, Pagan LU, Mota GAF. Influence of Atorvastatin on Intimal Hyperplasia in the Experimental Model. Arq Bras Cardiol. 2020 Oct;115(4):637-638. English, Portuguese. doi: 10.36660/abc.20200518. PMID: 33111861; PMCID: PMC8386986.

View History

ENPP1 inhibitor 32

ENPP1 inhibitor 32